论文部分内容阅读
目的观察前列地尔联合莫沙必利治疗糖尿病胃轻瘫临床疗效。方法收集我院2型糖尿病并发胃轻瘫患者60例,随机分为治疗组和对照组,每组各30例,对照组给予莫沙必利治疗,治疗组在对照组的基础上加用前列地尔,两组都给予降血糖治疗,并维持血糖相对稳定。两组均治疗4周,观察临床症状,行胃镜检查。结果前列地尔联合莫沙必利治疗组总体有效率为93.3%(28/30)明显高于对照组的73.3%(22/30),差异有统计学意义(P<0.05),没有明显的不良反应。结论在糖尿病综合治疗和血糖充分控制的前提下前列地尔联合莫沙必利治疗尿病性胃轻瘫,与单用莫沙必利治疗,疗效更优,安全可行。
Objective To observe the clinical efficacy of alprostadil plus mosapride in the treatment of diabetic gastroparesis. Methods Sixty patients with type 2 diabetes mellitus complicated with gastroparesis in our hospital were randomly divided into treatment group and control group, with 30 cases in each group. The control group was given mosapride, and the treatment group was added on the basis of the control group To Seoul, both groups were given hypoglycemic treatment, and maintain a relatively stable blood glucose. The two groups were treated for 4 weeks, observe the clinical symptoms, gastroscopy. Results The overall effective rate was 93.3% (28/30) in the prostaglandin plus mosapride group, which was significantly higher than that in the control group (73.3%, 22/30), with significant difference (P <0.05) Adverse reactions. Conclusion Alzheimer’s combined with mosapride in the treatment of diabetic gastroparesis under the premise of comprehensive treatment of diabetes and blood glucose, and more effective treatment with mosapride alone, the effect is better and safe and feasible.